Cancer Care Ontario | Cancer Care Ontario

You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

171 Results

Guidelines and Advice

Biochemotherapy for the Treatment of Metastatic Malignant Melanoma

Status: Archived
ID: 8-3

Sep 2011

Guidelines and Advice

Temozolomide for the Treatment of Metastatic Melanoma

Status: Archived
ID: 8-4

Sep 2011

Guidelines and Advice

Single-Agent Interleukin-2 in the Treatment of Metastatic Melanoma

Status: Archived
ID: 8-5
Version: 2

Sep 2011

Guidelines and Advice

Ifosfamide-based Combination Chemotherapy in Advanced Soft Tissue Sarcoma

Status: Archived
ID: 11-4

Sep 2011

Guidelines and Advice

Dose-intensive Chemotherapy with Growth Factor or Autologous Bone Marrow/Stem Cell Transplant Support in Advanced or Metastatic Adult Soft Tissue Sarcoma

Status: Archived
ID: 11-5

Sep 2011

Guidelines and Advice

The Role of Trastuzumab (Herceptin) in the Treatment of Women with HER2/neu-overexpressing Metastatic Breast Cancer

Status: Archived
ID: 1-15 Version 3
Version: 3

Sep 2011

Guidelines and Advice

Radionuclide Therapy for Patients with Neuroendocrine Tumors (NETs) in Ontario: Expert Panel Report

Status: Current
ID: GL-C50-01

Jan 2011

Guidelines and Advice

Systemic Therapy in the Curative Treatment of Head and Neck Squamous Cell Cancer

Status: Current
ID: 5-11
Version: 2

Jan 2022

Guidelines and Advice

Optimal Treatment Strategies for Localized Ewing's Sarcoma of Bone after Neoadjuvant Chemotherapy

Status: Current
ID: 11-6
Version: 2

Feb 2022

Guidelines and Advice

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer

Status: Current
ID: GL 1-22-A
Version: 2

Jul 2022

Guidelines and Advice

Recommendations on screening for breast cancer in average-risk women aged 40–74 years

Nov 2011

Drug

amsacrine

Other Name(s): AMSA P D® (Erfa)

Quick Link(s):

Sep 2011

Pages